{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:48Z","timestamp":1763754768940,"version":"3.45.0"},"reference-count":40,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2011,8,1]]},"DOI":"10.1188\/11.cjon.393-403","type":"journal-article","created":{"date-parts":[[2011,8,3]],"date-time":"2011-08-03T14:18:02Z","timestamp":1312381082000},"page":"393-403","source":"Crossref","is-referenced-by-count":12,"title":["Atypical Clinical Response Patterns to Ipilimumab"],"prefix":"10.1188","volume":"15","author":[{"given":"Blanca","family":"Ledezma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Binder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omid","family":"Hamid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2011,8,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High dose recombinant intereluekin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"M. Atkins","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"2","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4","volume":"23","author":"P. Attia","year":"2005","journal-title":"Journal of Clinical Oncology"},{"volume-title":"YERVOY\u2122 (ipilimumab) [Prescribing information]","year":"2011a","author":"Bristol-Meyers Squibb","key":"3"},{"key":"4","unstructured":"Bristol-Myers Squibb. (2011b). YERVOY\u2122 (ipilimumab) risk evaluation and mitigation strategy. Retrieved from <a target=\"_blank\" href='http:\/\/www.yervoy.com\/hcp\/rems.aspx'>http:\/\/www.yervoy.com\/hcp\/rems.aspx<\/a>"},{"key":"5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev.immunol.021908.132544","article-title":"Immune therapy for cancer","volume":"27","author":"M. Dougan","year":"2009","journal-title":"Annual Review of Immunology"},{"key":"6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0065-2776(06)90002-9","article-title":"Mechanisms of immune evasion by tumors","volume":"90","author":"C. Drake","year":"2006","journal-title":"Advances in Immunology"},{"key":"7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"G. Dunn","year":"2004","journal-title":"Immunity"},{"key":"8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.soc.2005.12.001","article-title":"Randomized trials in melanoma: An update","volume":"15","author":"A. Eggermont","year":"2006","journal-title":"Surgical Oncology Clinics of North America"},{"issue":"18","key":"9","article-title":"Kinetics of response to ipilimumab (MDX-010) in patients with stage III\/IV melanoma [Abstract 8525]","volume":"25","author":"O. Hamid","year":"2007","journal-title":"Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings"},{"issue":"3","key":"10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3747\/co.v16i3.447","article-title":"Adjuvant interferon alfa for melanoma: New evidence-based treatment recommendations?","volume":"16","author":"A. Hauschild","year":"2009","journal-title":"Current Oncology"},{"key":"11","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/cncr.23251","article-title":"Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma","volume":"112","author":"A. Hauschild","year":"2008","journal-title":"Cancer"},{"key":"12","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1073\/pnas.0712237105","article-title":"Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients","volume":"105","author":"F. Hodi","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"13","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"F. Hodi","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"15","key":"14","article-title":"Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma [Abstract 8509]","volume":"28","author":"F. Hodi","year":"2010","journal-title":"Journal of Clinical Oncology 2010 ASCO Annual Meeting Proceedings"},{"key":"15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"F. Hodi","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"16","unstructured":"Horner, M.J., Ries, L.A.G., Krapcho, M., Neyman, N., Aminou, R., Howlader, N., \u2026 Edwards, B.K. (Eds.). (2009). <i>SEER cancer statistics review, 1975-2006<\/i>. Retrieved from <a target=\"_blank\" href='http:\/\/seer.cancer.gov\/csr\/1975_2006'>http:\/\/seer.cancer.gov\/csr\/1975_2006<\/a>"},{"key":"17","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/0008-5472.CAN-05-4128","article-title":"Tumor-driven evolution of immunosuppressive networks during malignant progression","volume":"66","author":"R. Kim","year":"2006","journal-title":"Cancer Research"},{"key":"18","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I\/II study","volume":"12","author":"A. Maker","year":"2005","journal-title":"Annals of Surgical Oncology"},{"key":"19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","article-title":"Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma","volume":"29","author":"A. Maker","year":"2006","journal-title":"Journal of Immunotherapy"},{"key":"20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1089\/cbr.2008.0607","article-title":"Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis","volume":"24","author":"D. Minor","year":"2009","journal-title":"Cancer Biotherapy and Radiopharmaceuticals"},{"key":"21","unstructured":"National Comprehensive Cancer Network. (2010). <i>NCCN Clinical Practice Guidelines in Oncology\u2122: Melanoma<\/i> [v.1.2010]. Retrieved from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp'>http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp<\/a>"},{"key":"22","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.23086","article-title":"Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies","volume":"110","author":"S. O'Day","year":"2007","journal-title":"Cancer"},{"key":"23","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study","volume":"21","author":"S. O'Day","year":"2010","journal-title":"Annals of Oncology"},{"key":"24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","article-title":"Principles and use of anti-CTLA4 antibody in human cancer","volume":"18","author":"K. Peggs","year":"2006","journal-title":"Current Opinion in Immunology"},{"key":"25","doi-asserted-by":"publisher","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"G. Phan","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"26","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1158\/1078-0432.CCR-09-2376","article-title":"Do we need a different set of response assessment criteria for tumor immunotherapy?","volume":"15","author":"A. Ribas","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"27","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1586\/14760584.7.7.937","article-title":"Melanoma vaccines","volume":"7","author":"L. Riley","year":"2008","journal-title":"Expert Review of Vaccines"},{"key":"28","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2009-0028","article-title":"What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?","volume":"14","author":"C. Robert","year":"2009","journal-title":"Oncologist"},{"key":"29","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"C. Robert","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"30","first-page":"1","article-title":"The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases","volume":"8","author":"Y. Saenger","year":"2008","journal-title":"Cancer Immunity"},{"issue":"6","key":"31","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdp253","article-title":"Immunotherapy of distant metastatic disease","volume":"20","author":"D. Schadendorf","year":"2009","journal-title":"Annals of Oncology"},{"key":"32","first-page":"21","article-title":"Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview","volume":"19","author":"L. Serrone","year":"2000","journal-title":"Journal of Experimental and Clinical Cancer Research"},{"key":"33","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"J. Swann","year":"2007","journal-title":"Journal of Clinical Investigation"},{"key":"34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"2","author":"P. Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"key":"35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1084\/jem.190.3.355","article-title":"Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation","volume":"190","author":"A. van Elsas","year":"1999","journal-title":"Journal of Experimental Medicine"},{"key":"36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1034\/j.1600-0749.2003.00038.x","article-title":"Melanocyte-specific immune response in melanoma and vitiligo: Two faces of the same coin?","volume":"16","author":"A. Wankowicz-Kalinska","year":"2003","journal-title":"Pigment Cell Research"},{"key":"37","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","article-title":"Ipilimumab: Controversies in its development, utility, and autoimmune adverse events","volume":"58","author":"J. Weber","year":"2009","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"38","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"J. Weber","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"39","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria","volume":"15","author":"J. Wolchok","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"J. Wolchok","year":"2010","journal-title":"Lancet Oncology"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/GM23503X341732Q0.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:48:27Z","timestamp":1763754507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/15\/4\/atypical-clinical-response-patterns-ipilimumab"}},"subtitle":["Four Case Studies of Advanced Melanoma"],"short-title":[],"issued":{"date-parts":[[2011,8,1]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8,1]]}},"alternative-id":["GM23503X341732Q0"],"URL":"https:\/\/doi.org\/10.1188\/11.cjon.393-403","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2011,8,1]]}}}